FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2508810130> ?p ?o ?g. }

• W2508810130 abstract "Radiation-induced nephropathy is still dose limiting in radionuclide therapy of neuroendocrine tumors. We investigated the nephroprotective potential of the angiotensine converting enzyme inhibiting drug enalpril after [177Lu]-DOTATATE therapy in a murine model of radiation-induced nephropathy by renal scintigraphy. At first, the appropriate therapy activity to induce nephropathy was identified. Baseline scintigraphy (n = 12) entailed 12-min dynamic acquisitions after injection of 25 MBq [99mTc]-MAG3, which was followed by radionuclide therapy at four escalating activities of [177Lu]-DOTATATE: group (Gp) 1: 10 MBq; Gp 2: 20 MBq; Gp 3: 40 MBq; Gp 4: 65 MBq. Follow-up [99mTc]-MAG3 scintigraphy was carried out at days 9, 23, 44, and 65. The treatment activity for the intervention arm was selected on the basis of histological examination and declining renal function. In the second part, daily administration by gavage of 10 mg/kg/d enalapril or water (control group) was initiated on the day of radionuclide therapy. Follow-up scintigraphy was carried out at days 9, 23, 44, 65, and 86. We also created a non-therapy control group to detect therapy-independent changes of renal function over time. For all scintigraphies, mean renogram curves were analyzed and the fractional uptake rate (FUR; %I.D./min ± SEM) of the tracer by the kidneys was calculated as an index of renal clearance.At day 65 of follow-up, no significant change in the FUR relative to baseline (11.0 ± 0.3) was evident in radionuclide therapy groups 1 (11.2 ± 0.5) and 2 (10.1 ± 0.6), but FUR was significantly reduced in groups 3 (8.93 ± 0.6, p < 0.05) and 4 (6.0 ± 0.8, p < 0.01); we chose 40 MBq [177Lu]-DOTATATE (Gp 3) for the intervention study. Here, at the last day of follow-up (day 86), FUR was unaltered in enalapril-treated mice (11.8 ± 0.5) relative to the baseline group (12.4 ± 0.3) and non-therapy group (11.9 ± 0.8), whereas FUR in the control group had undergone a significant decline (9.3 ± 0.5; p < 0.01). Histological examination revealed prevention of kidney damage by enalapril treatment.Treatment with enalapril is effective for nephroprotection during radionuclide therapy with [177Lu]-DOTATATE in mice. Although these results are only limitedly transferable to human studies, enalapril might serve as a promising drug in the mitigation of nephropathy following treatment with [177Lu]-DOTATATE." @default.
• W2508810130 created "2016-09-16" @default.
• W2508810130 creator A5002308372 @default.
• W2508810130 creator A5004272744 @default.
• W2508810130 creator A5004699895 @default.
• W2508810130 creator A5027420105 @default.
• W2508810130 creator A5037412930 @default.
• W2508810130 creator A5044741435 @default.
• W2508810130 creator A5044995419 @default.
• W2508810130 creator A5048708393 @default.
• W2508810130 creator A5063536124 @default.
• W2508810130 creator A5077111140 @default.
• W2508810130 creator A5083220247 @default.
• W2508810130 date "2016-08-11" @default.
• W2508810130 modified "2023-10-11" @default.
• W2508810130 title "Nephroprotective effects of enalapril after [177Lu]-DOTATATE therapy using serial renal scintigraphies in a murine model of radiation-induced nephropathy" @default.
• W2508810130 cites W1523153743 @default.
• W2508810130 cites W1532412689 @default.
• W2508810130 cites W1599030510 @default.
• W2508810130 cites W1912220517 @default.
• W2508810130 cites W1922636298 @default.
• W2508810130 cites W1933764379 @default.
• W2508810130 cites W1935825021 @default.
• W2508810130 cites W1970926547 @default.
• W2508810130 cites W1975518883 @default.
• W2508810130 cites W1975563463 @default.
• W2508810130 cites W1977199347 @default.
• W2508810130 cites W1979717884 @default.
• W2508810130 cites W1985061998 @default.
• W2508810130 cites W1988986189 @default.
• W2508810130 cites W1989552774 @default.
• W2508810130 cites W1993744189 @default.
• W2508810130 cites W1993899353 @default.
• W2508810130 cites W1994118792 @default.
• W2508810130 cites W2009629472 @default.
• W2508810130 cites W2016852654 @default.
• W2508810130 cites W2018710311 @default.
• W2508810130 cites W2024035978 @default.
• W2508810130 cites W2027511464 @default.
• W2508810130 cites W2029000245 @default.
• W2508810130 cites W2031048655 @default.
• W2508810130 cites W2040950618 @default.
• W2508810130 cites W2043708980 @default.
• W2508810130 cites W2047558841 @default.
• W2508810130 cites W2071340159 @default.
• W2508810130 cites W2075075102 @default.
• W2508810130 cites W2097512974 @default.
• W2508810130 cites W2116119132 @default.
• W2508810130 cites W2123859260 @default.
• W2508810130 cites W2125398839 @default.
• W2508810130 cites W2154245012 @default.
• W2508810130 cites W2162050146 @default.
• W2508810130 cites W2170797403 @default.
• W2508810130 cites W2172082143 @default.
• W2508810130 cites W2266247096 @default.
• W2508810130 cites W2428254824 @default.
• W2508810130 cites W4211005640 @default.
• W2508810130 cites W4296766361 @default.
• W2508810130 doi "https://doi.org/10.1186/s13550-016-0219-2" @default.
• W2508810130 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4980865" @default.
• W2508810130 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27515447" @default.
• W2508810130 hasPublicationYear "2016" @default.
• W2508810130 type Work @default.
• W2508810130 sameAs 2508810130 @default.
• W2508810130 citedByCount "9" @default.
• W2508810130 countsByYear W25088101302017 @default.
• W2508810130 countsByYear W25088101302018 @default.
• W2508810130 countsByYear W25088101302019 @default.
• W2508810130 countsByYear W25088101302020 @default.
• W2508810130 countsByYear W25088101302021 @default.
• W2508810130 countsByYear W25088101302022 @default.
• W2508810130 crossrefType "journal-article" @default.
• W2508810130 hasAuthorship W2508810130A5002308372 @default.
• W2508810130 hasAuthorship W2508810130A5004272744 @default.
• W2508810130 hasAuthorship W2508810130A5004699895 @default.
• W2508810130 hasAuthorship W2508810130A5027420105 @default.
• W2508810130 hasAuthorship W2508810130A5037412930 @default.
• W2508810130 hasAuthorship W2508810130A5044741435 @default.
• W2508810130 hasAuthorship W2508810130A5044995419 @default.
• W2508810130 hasAuthorship W2508810130A5048708393 @default.
• W2508810130 hasAuthorship W2508810130A5063536124 @default.
• W2508810130 hasAuthorship W2508810130A5077111140 @default.
• W2508810130 hasAuthorship W2508810130A5083220247 @default.
• W2508810130 hasBestOaLocation W25088101301 @default.
• W2508810130 hasConcept C126322002 @default.
• W2508810130 hasConcept C126894567 @default.
• W2508810130 hasConcept C134018914 @default.
• W2508810130 hasConcept C159641895 @default.
• W2508810130 hasConcept C27016395 @default.
• W2508810130 hasConcept C2775940317 @default.
• W2508810130 hasConcept C2779902710 @default.
• W2508810130 hasConcept C2780091579 @default.
• W2508810130 hasConcept C2781184683 @default.
• W2508810130 hasConcept C2989005 @default.
• W2508810130 hasConcept C2993559085 @default.
• W2508810130 hasConcept C555293320 @default.
• W2508810130 hasConcept C71924100 @default.
• W2508810130 hasConcept C84393581 @default.
• W2508810130 hasConceptScore W2508810130C126322002 @default.
• W2508810130 hasConceptScore W2508810130C126894567 @default.

• next